Nrx Pharmaceuticals Inc (NRXP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 1,225 | 0 | 0 | 0 | 0 |
| Cost of Goods | 505 | N/A | N/A | N/A | N/A |
| Gross Profit | 720 | N/A | N/A | N/A | N/A |
| Operating Expenses | 17,449 | 18,502 | 27,837 | 44,335 | 115,796 |
| Operating Income | -16,224 | -18,502 | -27,837 | -44,335 | -115,796 |
| Interest Expense | 671 | 230 | 120 | 0 | 18 |
| Other Income | -11,727 | -6,394 | -2,193 | 4,581 | 22,751 |
| Pre-tax Income | -28,622 | -25,126 | -30,150 | -39,754 | -93,063 |
| Net Income Continuous | -28,622 | -25,126 | -30,150 | -39,754 | -93,063 |
| Net Income | $-28,622 | $-25,126 | $-30,150 | $-39,754 | $-93,063 |
| EPS Basic Total Ops | -1.34 | -2.36 | -3.98 | -6.00 | -74.40 |
| EPS Basic Continuous Ops | -1.34 | -2.36 | -3.98 | -6.04 | -19.84 |
| EPS Diluted Total Ops | -1.34 | -2.36 | -3.98 | -6.00 | -74.40 |
| EPS Diluted Continuous Ops | -1.34 | -2.36 | -3.98 | -6.04 | -19.84 |
| EPS Diluted Before Non-Recurring Items | -1.25 | -1.96 | -3.70 | -6.80 | -74.10 |
| EBITDA(a) | $-16,081 | $-18,497 | $-27,832 | $-44,331 | $-115,794 |